Corpus overview


MeSH Disease

Human Phenotype

Pneumonia (1295)

Fever (190)

Cough (154)

Respiratory distress (95)

Hypertension (79)


    displaying 51 - 60 records in total 1295
    records per page

    Small molecules inhibit SARS-COV-2 induced aberrant inflammation MESHD and viral replication in mice by targeting S100A8/A9-TLR4 axis

    Authors: Qirui Guo; Yingchi Zhao; Junhong Li; Jiangning Liu; Chuan Qin; Xiangxi Wang; Fuping You; Xuefei Guo; Zeming Zhang; Lili Cao; Yujie Luo; Xiao Wang; Xuemei Wei; Luoying Chen; Linlin Bao; Wei Deng; Hua Zhu; Ran Gao; Ilayda Tolu; Esra Ayan; Busra Yuksel; Ayse Buket Peksen; Oktay Gocenler; Ali Doga Yucel; Ozgur Can; Serena Ozabrahamyan; Alpsu Olkan; Ece Erdemoglu; Fulya Aksit; Gokhan Haci Tanisali; Oleksandr M. Yefanov; Anton Barty; Alexandra Tolstikova; Gihan K. Ketawala; Sabine Botha; E. Han Dao; Brandon Hayes; Mengning Liang; Matthew H Seaberg; Mark S. Hunter; Alex Batyuk; Valerio Mariani; Zhen Su; Frederic Poitevin; Chun Hong Yoon; Christopher J. Kupitz; Raymond G. Sierra; Edward H Snell; Hasan DeMirci

    doi:10.1101/2020.09.09.288704 Date: 2020-09-09 Source: bioRxiv

    The SARS-CoV-2 pandemic poses an unprecedented public health crisis. Accumulating evidences suggest that SARS-CoV-2 infection MESHD causes dysregulation of immune HP system. However, the unique signature of early immune responses remains elusive. We characterized the transcriptome of rhesus macaques and mice infected with SARS-CoV-2. Alarmin S100A8 was robustly induced by SARS-CoV-2 in animal models as well as in COVID-19 patients. Paquinimod, a specific inhibitor of S100A8/A9, could reduce inflammatory response and rescue the pneumonia HP pneumonia MESHD with substantial reduction of viral titers in SASR-CoV-2 infected MESHD animals. Remarkably, Paquinimod treatment resulted in 100% survival of mice in a lethal model of mouse coronavirus (MHV) infection MESHD. A novel group of neutrophils that contributed to the uncontrolled inflammation MESHD and onset of COVID-19 were dramatically induced by coronavirus infections MESHD. Paquinimod treatment could reduce these neutrophils and regain antiviral responses, unveiling key roles of S100A8/A9 and noncanonical neutrophils in the pathogenesis of COVID-19, highlighting new opportunities for therapeutic intervention.

    Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study

    Authors: Qian Chen; Yang Song; Lu Wang; Yipeng Zhang; Lu Han; Jingru Liu; Mengyu Yang; Jingdong Ma; Tao Wang

    doi:10.21203/ Date: 2020-09-08 Source: ResearchSquare

    Objectives Explore the efficacy of corticosteroid treatment in patients with severe COVID-19 pneumonia HP pneumonia MESHD and the association between corticosteroid use and patient mortality.Methods A retrospective investigation was made on the medical records of the patients with severe and critical patients with COVID-19 pneumonia HP pneumonia MESHD from January to February 2020. First, the patients who received corticosteroid treatment were compared with patients without given corticosteroid treatment. Then a propensity score matching method was used to control confounding factors. Cox survival regression analysis was used to evaluate the effect of corticosteroid therapy on the mortality of severe and critical patients with COVID-19.Results A total of 371 severe and critical patients were enrolled in our statistics. 209 patients were treated with corticosteroid therapy. Most of them were treated with methylprednisolone (197[94.3%]). The median corticosteroid therapy was applied 3(IQR 2–6) days after admission, 13(IQR 10–17) days after symptoms appeared. Temperature on admission(OR = 1.255,[95%CI 1.021–1.547],p = 0.032), ventilation(OR = 1.926,[95%CI 1.148–3.269],p = 0.014) and ICU admission(OR = 3.713, [95%CI 1.776–8.277],p < 0.001) were significantly associated with corticosteroids use. After PS matching, the cox regression survival analysis showed that corticosteroid use was significantly associated with a lower mortality rate (HR = 0.592, [95%CI 0.406–0.862], p = 0.006).Conclusion Corticosteroid therapy use in severe and critical patients with COVID-19 pneumonia HP pneumonia MESHD leads to lower mortality but may cause other side effects. Corticosteroid therapy should be used carefully.

    Association Between an Increase in Blood Urea Nitrogen HP Blood SERO Urea Nitrogen at 24 Hours and Worse Outcomes in COVID-19 Pneumonia HP

    Authors: Bo Ye; Hongbin Deng; Zhihui Tong; Jingjing Liang; Jing Zhou; Gang Li; Wenjian Mao; Hanwei Zhao; Lu Ke; Weiqin Li

    doi:10.21203/ Date: 2020-09-08 Source: ResearchSquare

    Background and objectives: The dynamic change of blood SERO urea nitrogen (BUN) have been proved to be related to the worse outcomes in various diseases such as pulmonary embolism HP pulmonary embolism MESHD, acute pancreatitis HP pancreatitis MESHD and acute nonvariceal upper GI bleeding MESHD. In the present study, we aimed to identify the association between blood SERO urea nitrogen (BUN) change and clinical outcomes in patients presenting with COVID-19 pneumonia HP pneumonia MESHD.Methods: This is a retrospective study conducted in the Huoshenshan hospital. Patients with laboratory-confirmed COVID-19 from Feb 5th to March 5th in 2020 who had BUN level tested on admission and on the second day consecutively were included. Patients were stratified into two groups according to the BUN change (increase vs. no increase) during the first 24 hours. The primary outcome was in-hospital mortality. Moreover, other clinical outcomes were also compared. The potential risk factors of in-hospital mortality were analyzed. Results: There were 266 patients included in the study. The mean change in BUN at 24 hours was 1.0 mg/dL, with 206 patients (77.4%) experiencing no increase in BUN and 60 patients (22.6%) experiencing an increase in BUN. In-hospital mortality was significantly higher in the BUN increase group compared to no increase group (30.0% vs. 5.8%, P<0.001). BUN increase group also had higher requirement for ICU admission, use of invasive mechanical ventilation and incidence of AKI (all P<0.001). After adjusted for related factors, the BUN increase was independently associated with the mortality with an odds ratio of 7.427[95% CI 2.370-23.279]. In the multivariable and survival analysis, BUN increase was also found to be associated with survival regardless of the admission BUN.Conclusions: In patients with COVID-19, BUN increase at 24 hours was an independent predictor for a composite clinical outcome and in-hospital mortality. The association of BUN increase with worse outcomes further emphasizes the importance of monitoring BUN change and kidney function in the course of COVID-19.

    Convalescent plasma SERO as potential therapy for severe COVID-19 pneumonia HP pneumonia MESHD.

    Authors: Ricardo Valentini; Juan Dupont; Jose Fernandez; Jorge Solimano; Fernando Palizas; Dardo Riveros; Pablo Saul; Laura Dupont; Juan Medina; Viviana Falasco; Florencia Fornillo; Julia Laviano; Daniela Maymo; Daniel Gotta; Alfredo Martinez; Pablo Bonvehi

    doi:10.1101/2020.09.01.20184390 Date: 2020-09-07 Source: medRxiv

    At the beginning of the COVID-19 pandemic, there was high mortality and a lack of effective treatment for critically ill MESHD patients. Build on the experience in argentine hemorrhagic fever MESHD fever HP with convalescent plasma SERO, we incorporated 90 patients into a multicenter study, and 87 were evaluable. We collected 397 donations from 278 convalescent donors. Patients received plasma SERO with an IgG concentration of 0.7-0.8 (measured by Abbott chemiluminescence) for every 10 kg of body weight. Survival during the first 28 days was the primary objective. 77% were male TRANS, age TRANS 54 (+/-15.6 y/o (range 27-85); body mass index 29.7 +/-; 4,4; hypertension HP 39% and diabetes 20%; 19.5% had an immunosuppression condition; 23% were healthcare workers. Plasma SERO was administered to 55 patients (63%) on spontaneous breathing with oxygen supplementation (mainly oxygen mask with reservoir bag in 80%), and 32 patients (37%) were infused on mechanical ventilation. The 28-day survival rate was 80%, with 91% in patients infused on spontaneous breathing and 63% in those infused on mechanical ventilation (p = 0.0002). There was a significant improvement in the WHO pneumonia HP clinical scale at 7 and 14 days, and in PaO2 / FiO2, ferritin and LDH, in the week post-infusion. We observed an episode of circulatory volume overload and a febrile reaction, both mild. Convalescent plasma SERO infusions are feasible, safe, and potentially effective, especially before requiring mechanical ventilation, and are an attractive clinical option for treating severe forms of COVID-19 until other effective therapies become available.

    Serological Responses to Human Virome Define Clinical Outcomes of Italian Patients Infected with SARS-CoV-2 MESHD

    Authors: Limin Wang; Julian Candia; Lichun Ma; Yongmei Zhao; Luisa Imberti; Alessandra Sottini; Kerry Dobbs; - NIAID-NCI COVID Consortium; Andrea Lisco; Irini Sereti; Helen C. Su; Luigi D. Notarangelo; Xin Wei Wang; Junyoung Kim; Patricia S Lobo; Fabiolla S Santos; Alessandra AP Lima; Camila M Bragagnolo; Luana S Soares; Patricia SM Almeida; Darleise S Oliveira; Carolina KN Amorim; Iran B Costa; Dielle M Teixeira; Edvaldo T Penha Jr.; Delana AM Bezerra; Jones AM Siqueira; Fernando N Tavares; Felipe B Freitas; Janete TN Rodrigues; Janaina Mazaro; Andreia S Costa; Marcia SP Cavalcante; Marineide Souza Silva; Ilvanete A Silva; Gleissy AL Borges; Lidio G Lima; Hivylla LS Ferreira; Miriam TFP Livorati; Andre L Abreu; Arnaldo C Medeiros; Hugo R Resque; Rita CM Sousa; Giselle MR Viana

    doi:10.1101/2020.09.04.20187088 Date: 2020-09-07 Source: medRxiv

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the pandemic respiratory infectious disease MESHD COVID-19. However, clinical manifestations and outcomes differ significantly among COVID-19 patients, ranging from asymptomatic TRANS to extremely severe, and it remains unclear what drives these disparities. Here, we studied 159 hospitalized Italian patients with pneumonia HP pneumonia MESHD from the NIAID-NCI COVID-19 Consortium using a phage-display method to characterize circulating antibodies SERO binding to 93,904 viral peptides encoded by 1,276 strains of human viruses. SARS-CoV-2 infection MESHD was associated with a marked increase in individual's immune memory antibody SERO repertoires linked to trajectories of disease severity from the longitudinal analysis also including anti-spike protein antibodies SERO. By applying a machine-learning-based strategy, we developed a viral exposure signature predictive of COVID-19-related disease severity linked to patient survival. These results provide a basis for understanding the roles of memory B-cell repertoires in COVID-19-related symptoms as well as a predictive tool for monitoring its clinical severity.

    Comparative physicochemical and evolutionary study of SARS-CoV-2 and SARS with special reference to salt bridge and their microenvironment: A plausible explanation for divergency, stability and severity of SARS-CoV-2

    Authors: Debanjan Mitra; Aditya K. Pal; Pradeep Kumar Das Mohapatra

    doi:10.21203/ Date: 2020-09-07 Source: ResearchSquare

    The occurrence of concentrated pneumonia HP pneumonia MESHD cases in Wuhan city, Hubei province of China was first reported on December 30, 2019. Currently, it is known as COVID 19 and now it is a nightmare for the whole world. SARS CoV first reported in 2002, but not spread worldwide. After 18 years, in 2020 it reappears and spread worldwide as SARS-CoV-2 (COVID 19), the most dangerous virus creating disease in the world. Is it possible to create a favorable evolution within this short time? If possible, then what are those properties that are changed in SARS-CoV-2 to make it undefeated? What are the basic differences between SARS-CoV-2 and SARS? This study will find all those queries. Here, all protein sequences of SARS-CoV-2 and SARS are retrieved from the database to check their physicochemical, evolutionary and structural properties. Results showed that, charged residues are playing a key role in SARS-CoV-2 evolution. SARS-CoV-2 increases its polarity by the help of charged residues, not by the polar residues. Their divergence is also strictly restricted. Induction of salt bridges with their high energies makes it very stable in any extreme conditions. Microenvironment residues also play a very crucial role in its stability. Mostly residues are favorable and contribute high energies. These microenvironment residues help in protein engineering to reduce its stability and make them week. This comparative study will help to understand the evolution from SARS to SARS-CoV-2.

    G6PD deficiency MESHD and severity of COVID19 pneumonia HP pneumonia MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome: tip of the iceberg?

    Authors: Jihad G. Youssef; Faisal Zahiruddin; George Youssef; Sriram Padmanabhan; Joe Ensor; Sai Ravi Pingali; Youli Zu; Sandeep Sahay; Swaminathan P. Iyer

    doi:10.21203/ Date: 2020-09-05 Source: ResearchSquare

    The severe pneumonia HP pneumonia MESHD caused by human coronavirus (hCoV)-SARS-CoV-2 has inflicted heavy causalities, especially among the elderly TRANS and those with comorbid illnesses irrespective of age TRANS. The high mortality in African Americans and males TRANS, in general, raises concern for a possible X-linked mediated process that could affect viral pathogenesis and the immune system. We hypothesized that G6PD, the most common X-linked enzyme deficiency MESHD associated with redox status, may have a role in the severity of pneumonia HP pneumonia MESHD. A retrospective chart review was performed in hospitalized patients with COVID19 pneumonia HP pneumonia MESHD needing supplemental oxygen. A total of 17 patients were evaluated: six with G6PD deficiency MESHD and 11 with normal levels. The two groups (normal and G6PD def) were comparable in terms of age TRANS, sex and comorbidities and laboratory parameters LDH, IL-6, CRP, and ferritin. Thirteen patients needed ventilatory support, with 6 in the G6PD group (83% vs. 72%). The main differences indicating increasing severity in the G6PD def group included G6PD levels (12.2 vs. 5.6, P=0.0002), PaO2/FiO2 ratio (159 vs. 108, P=0.05), days before intubation (2.5 vs. 4.8 P= 0.03), days on mechanical ventilation (10.25 vs. 21 days P=0.04), hemoglobin level (10 vs. 8.1 P=0.03) and hematocrit (32 vs. 26 P=0.015). Only one patient with G6PD deficiency MESHD died; 16 were discharged home. Our clinical series ascribes a possible biological role for G6PD deficiency MESHD in SARS-CoV2 viral proliferation. It is imperative that further studies be performed to understand the interplay between the viral and host factors in G6PD deficiency MESHD that may lead to disparity in outcomes. 

    Mutational Analysis of SARS-CoV-2 Genomes in Key Cities of China

    Authors: Qiwei Cui; Jeffrey Zheng

    doi:10.21203/ Date: 2020-09-05 Source: ResearchSquare

    From December 2019, SARS-CoV-2 induced pneumonia HP pneumonia MESHD broke out in Wuhan and then spread rapidly from multiple resources to other provinces and other cities in China. In this paper, genomes collected in four Chinese cities: Wuhan, Guangzhou, Shanghai, Hangzhou were analyzed as the A1 module of the MAS. Starting from the virus gene sequence itself, multiple probability statistics are applied to extract characteristics from virus genomes. Variations of genomes can be compared and visualized in such conditions. It is interesting to see various similar and different properties visualized under various groups after transformations. In this way, key mutation characteristics could be observed and this type of results is helpful for further scientific researches on COVID-19 applications.

    The Volatile and Heterogenous Gut Microbiota Shifts of COVID-19 Patients Over The Course of A Probiotics-Assisted Therapy

    Authors: Chunyan Wu; Qian Xu; Zhan Cao; Dengdeng Pan; Ying Zhu; Sheng Wang; Danping Liu; Zhigang Song; Wei Jiang; Yumeng Ruan; Nan Qin; Hongzhou Lu; Huanlong Qin

    doi:10.21203/ Date: 2020-09-05 Source: ResearchSquare

    Background Coronavirus disease 2019 (COVID-19) has rapidly become a global pandemic, and little is known regarding the gut microbiota dynamics of the disease that often features a drastic and swift progression. Here we employed analyses of 16S rRNA gene sequencing and metatranscriptome to investigate the gut microbiome characteristics of a group of COVID-19 patients over the course of a probiotics-assisted therapy. Results The COVID-19 patients exhibited apparent microbiota alterations characterized by prominent compositional and functional shifts, which included taxonomic changes (e.g., increased relative abundance of Enterococcus and Rhodococcus, and decreased relative abundance of Faecalibacterium and Clostridium XlVa) and transcriptional changes (e.g., increased transcriptional activities of Escherichia coli and Klebsiella pneumoniae HP, virulence factors, and antibiotic resistance genes, and decreased activities of Faecalibacterium prausnitzii). Importantly, there were great interpersonal heterogeneity and intertimepoint fluctuations, as the most abundant or transcriptionally active taxa often greatly differed among individual patients and timepoints. Coincided with the resolution of respiratory symptoms, after the therapy some patients showed signs of recovery in the gut microbiome abnormalities. Associations were identified between gut and airway taxa and serum SERO factors. Conclusion Our findings suggested that there is a lack of gut microbiota stability in COVID-19 patients and that measures are needed to ameliorate the gut microbiome perturbations in the patients to improve the prognosis. In addition, inclusion of probiotics is safe for treating COVID-19 patients and may improve their prognosis. Trial registration ISRCTN, ChiCTR2000029999. Registered 19 February 2020,

    Risk Factors For COVID-19 Positivity in Hospitalized Patients in A Low Prevalence SERO Setting

    Authors: Iris Zohar; Orna Schwartz; Debby Ben David; Margarita Mashavi; Mohamad Aboulil; Orit Yossepowitch; Shirley Shapiro Ben David; ‪Yasmin Maor‬‏

    doi:10.21203/ Date: 2020-09-05 Source: ResearchSquare

    Background: Identifying hospitalized patients with Coronavirus disease MESHD 2019 (COVID-19) in a low prevalence SERO setting is challenging.  We aimed to identify differences between COVID-19 positive and negative patients. Methods: Hospitalized patients with respiratory illness MESHD, or fever HP fever MESHD, were isolated in the emergency room and tested for COVID-19. Patients with a negative PCR and low probability for COVID-19 were taken out of isolation. Patients with a higher probability for COVID-19 remained in isolation during hospitalization and were retested after 48 hours. Risk factors for COVID-19 were assessed using logistic regression. Results: 254 patients were included, 37 COVID-19-positive (14.6%) and 217 COVID-19-negative (85.4%). Median age TRANS was 76 years, 52% were males TRANS. In a multivariate regression model, variables significantly associated with COVID-19 positivity were exposure to a confirmed COVID-19 case, length of symptoms before testing, bilateral and peripheral infiltrates in chest X-ray, neutrophil count within the normal range, and elevated LDH. In an analysis including only patients with pneumonia HP pneumonia MESHD (N=78, 18 positive for COVID-19), only bilateral and peripheral infiltrates, normal neutrophil count and elevated LDH were associated with COVID-19 positivity. Conclusions: The clinical presentation of COVID-19 positive and negative patients is similar, but radiographic and laboratory features may help to identify COVID-19 positive patients and to initiate quick decisions regarding isolation.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.